JP2001510028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001510028A5 JP2001510028A5 JP2000502802A JP2000502802A JP2001510028A5 JP 2001510028 A5 JP2001510028 A5 JP 2001510028A5 JP 2000502802 A JP2000502802 A JP 2000502802A JP 2000502802 A JP2000502802 A JP 2000502802A JP 2001510028 A5 JP2001510028 A5 JP 2001510028A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- vector
- expression vector
- polypeptide
- vascular proliferative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 239000013604 expression vector Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/897,333 US6177272B1 (en) | 1997-07-21 | 1997-07-21 | Method for treating vascular proliferative diseases with p27 and fusions thereof |
| US08/897,333 | 1997-07-21 | ||
| PCT/US1998/015025 WO1999003508A2 (en) | 1997-07-21 | 1998-07-21 | METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001510028A JP2001510028A (ja) | 2001-07-31 |
| JP2001510028A5 true JP2001510028A5 (OSRAM) | 2006-01-05 |
Family
ID=25407780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000502802A Pending JP2001510028A (ja) | 1997-07-21 | 1998-07-21 | ｐ２７およびその融合物で血管増殖性疾患を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6177272B1 (OSRAM) |
| EP (1) | EP0998307B1 (OSRAM) |
| JP (1) | JP2001510028A (OSRAM) |
| AT (1) | ATE342067T1 (OSRAM) |
| AU (1) | AU8502198A (OSRAM) |
| CA (1) | CA2295199C (OSRAM) |
| DE (1) | DE69836139T2 (OSRAM) |
| WO (1) | WO1999003508A2 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US6413943B1 (en) | 1999-03-01 | 2002-07-02 | Cell Genesys, Inc. | Methods and reagents for inhibiting proliferation of smooth muscle cells |
| IL145067A0 (en) * | 1999-03-01 | 2002-06-30 | Cell Genesys Inc | Nucleic acid composition containing a first sequence encoding a chimeric cyclin-dependent kinase protein and a second sequence encoding an adenovirus e4 protein |
| US6420345B1 (en) * | 1999-03-01 | 2002-07-16 | Cell Genesys, Inc. | Methods and reagents for inhibiting angiogenesis |
| JP4684512B2 (ja) * | 1999-09-22 | 2011-05-18 | 信之 宮坂 | ｐ２１Ｃｉｐ１リウマチ治療剤 |
| US20040243097A1 (en) * | 2000-05-12 | 2004-12-02 | Robert Falotico | Antiproliferative drug and delivery device |
| US7300662B2 (en) | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
| US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| US8236048B2 (en) * | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| AU9486901A (en) * | 2000-09-29 | 2002-04-08 | Cordis Corp | Coated medical devices |
| US20020051730A1 (en) * | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
| US7261735B2 (en) * | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
| US20020111590A1 (en) * | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
| US20030013638A1 (en) * | 2001-01-22 | 2003-01-16 | Marks Andrew R. | P27 prevents cellular migration |
| US20020098998A1 (en) * | 2001-01-22 | 2002-07-25 | Marks Andrew R. | P27 prevents cellular migration |
| US7195640B2 (en) * | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
| US20030065377A1 (en) * | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
| US20030065345A1 (en) * | 2001-09-28 | 2003-04-03 | Kevin Weadock | Anastomosis devices and methods for treating anastomotic sites |
| US7108701B2 (en) * | 2001-09-28 | 2006-09-19 | Ethicon, Inc. | Drug releasing anastomosis devices and methods for treating anastomotic sites |
| WO2006031210A1 (en) | 2003-05-29 | 2006-03-23 | Board Of Regents, The University Of Texas Systems | Jabi as a prognostic marker and a therapeutic target for human cancer |
| US7833339B2 (en) | 2006-04-18 | 2010-11-16 | Franklin Industrial Minerals | Mineral filler composition |
| US8221738B2 (en) * | 2008-02-19 | 2012-07-17 | Celladon Corporation | Method for enhanced uptake of viral vectors in the myocardium |
| KR20220051164A (ko) | 2019-07-05 | 2022-04-26 | 아이오엠엑스 테라퓨틱스 아게 | Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도 |
| WO2022008027A1 (en) | 2020-07-06 | 2022-01-13 | Iomx Therapeutics Ag | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US6355774B1 (en) | 1994-01-07 | 2002-03-12 | Fred Hutchinson Cancer Research Center | Isolated p27 protein |
| US5688665A (en) | 1994-01-07 | 1997-11-18 | Fred Hutchinson Cancer Research Center | Isolated nucleic acid molecules encoding the p27 KIP-1 protein |
| US6316208B1 (en) | 1994-01-07 | 2001-11-13 | Memorial Sloan-Kettering Cancer Center | Methods for determining isolated p27 protein levels and uses thereof |
| US6242575B1 (en) | 1994-01-07 | 2001-06-05 | Fred Hutchinson Institute For Cancer Research | Antibodies for detecting p27 protein |
| AU2770695A (en) | 1994-07-15 | 1996-02-16 | Fred Hutchinson Cancer Research Center | Isolated p27 protein and methods for its production and use |
| AU5297496A (en) * | 1995-02-17 | 1996-09-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of preparation and use of recombinant adenoviral vectors |
| US5962424A (en) * | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
| US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| US6541197B2 (en) * | 1996-01-22 | 2003-04-01 | Human Gene Therapy Research Institute | Vehicles for stable transfer of green fluorescent protein gene and methods of use for same |
| US5672508A (en) * | 1996-01-23 | 1997-09-30 | Mitotix, Inc. | Inhibitors of cell-cycle progression, and uses related thereto |
| WO1998021350A1 (en) * | 1996-11-13 | 1998-05-22 | Board Of Regents, The University Of Texas System | Diminishing viral gene expression by promoter replacement |
-
1997
- 1997-07-21 US US08/897,333 patent/US6177272B1/en not_active Expired - Fee Related
-
1998
- 1998-07-21 EP EP98935852A patent/EP0998307B1/en not_active Expired - Lifetime
- 1998-07-21 WO PCT/US1998/015025 patent/WO1999003508A2/en not_active Ceased
- 1998-07-21 AT AT98935852T patent/ATE342067T1/de not_active IP Right Cessation
- 1998-07-21 AU AU85021/98A patent/AU8502198A/en not_active Abandoned
- 1998-07-21 CA CA002295199A patent/CA2295199C/en not_active Expired - Fee Related
- 1998-07-21 JP JP2000502802A patent/JP2001510028A/ja active Pending
- 1998-07-21 DE DE69836139T patent/DE69836139T2/de not_active Expired - Fee Related
-
2000
- 2000-11-07 US US09/708,276 patent/US6884431B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4659068B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| US7112659B2 (en) | OB fusion protein compositions and methods | |
| AU2005287383B2 (en) | Self-assembling nanoparticle drug delivery system | |
| AU752086B2 (en) | Mutagenized il13-based chimeric molecules | |
| CN1087344C (zh) | 转化生长因子α－H1 | |
| JPH09503665A (ja) | エンドソーム分解活性粒子 | |
| JP2005530484A5 (OSRAM) | ||
| KR20020065517A (ko) | 인터페론 감마 접합체 | |
| CA2232264C (en) | Variants of human recombinant interferon-.gamma. (rhu-ifn-.gamma.) with increased thermal stability | |
| JP2001518304A (ja) | アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用 | |
| JP2003047492A (ja) | ヒトケモカインベータ−９ | |
| BRPI0615538A2 (pt) | proteìna de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de produção de um polipeptìdio, composição farmacêutica, composição alimentar, método para a redução do peso corpóreo, método para o tratamento de diabetes, método para aumentar a vida média de um peptìdio ou uma proteìna terapêutica recombinante em um indivìduo, método para aumentar a eficácia de um peptìdio ou proteìna terapêutica, método para o tratamento de diabetes ou redução do peso corpóreo | |
| JP2000511762A (ja) | ケラチノサイト増殖因子アナログ | |
| BG108256A (bg) | Интерферон-гама полипептидни разновидности | |
| US7223731B2 (en) | Thrombospondin-1 type 1 repeat polypeptides | |
| KR100686356B1 (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 | |
| CA2356009C (en) | Vascular endothelial growth factor-x | |
| US20020137679A1 (en) | COMP/TSP-1, COMP/TSP-2 and other TSP chimeric proteins | |
| CN102574907A (zh) | 修饰的人肿瘤坏死因子受体i多肽或其片段以及制备它们的方法 | |
| JP2553425B2 (ja) | トロンビン結合性物質及びその製造法 | |
| JP2004518410A5 (OSRAM) | ||
| CN121045390A (zh) | 融合蛋白及其应用 | |
| JP2002522083A (ja) | 単離および精製されたヒト可溶性グアニリルシクラーゼα１／β１（ｈｓＧＣα１／β１） | |
| JP2003052387A (ja) | 線維芽細胞増殖因子１３ | |
| JP2009100747A (ja) | トランスフォーミング増殖因子αＨＩＩ |